MedPath

Genetic Modifiers for 22q11.2 Syndrome

Completed
Conditions
22q11.2 Deletion Syndrome
Interventions
Other: Observation
Registration Number
NCT00916955
Lead Sponsor
State University of New York - Upstate Medical University
Brief Summary

The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome chips and microarray analysis. Blood samples are collected for DNA from every patient who consents from the VCFS Center at Upstate Medical University. They are examined for phenotypic features consistent with our typical clinical evaluation. The information from these examinations will be entered anonymously into a database. Genomic information is then matched to clinical phenotype with appropriate statistical method applied.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • FISH confirmed diagnosis of 22q11.2 deletion syndrome
Exclusion Criteria
  • none

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Individuals with 22q11.2 deletionsObservationIndividuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
Primary Outcome Measures
NameTimeMethod
gene signal strength4 years
Secondary Outcome Measures
NameTimeMethod
physical phenotype4 years

Trial Locations

Locations (1)

VCFS International Center

🇺🇸

Syracuse, New York, United States

© Copyright 2025. All Rights Reserved by MedPath